Cancer Chemotherapy and Pharmacology

, Volume 50, Issue 2, pp 167–169

c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571)

Authors

  • Marc Hotfilder
    • University Children's Hospital Muenster, Department of Pediatric Hematology and Oncology, University of Muenster, Albert-Schweitzer-Str. 33, 48129 Muenster, Germany
  • Claudia Lanvers
    • University Children's Hospital Muenster, Department of Pediatric Hematology and Oncology, University of Muenster, Albert-Schweitzer-Str. 33, 48129 Muenster, Germany
  • Heribert Jürgens
    • University Children's Hospital Muenster, Department of Pediatric Hematology and Oncology, University of Muenster, Albert-Schweitzer-Str. 33, 48129 Muenster, Germany
  • Joachim Boos
    • University Children's Hospital Muenster, Department of Pediatric Hematology and Oncology, University of Muenster, Albert-Schweitzer-Str. 33, 48129 Muenster, Germany
  • Josef Vormoor
    • University Children's Hospital Muenster, Department of Pediatric Hematology and Oncology, University of Muenster, Albert-Schweitzer-Str. 33, 48129 Muenster, Germany
Short Communication

DOI: 10.1007/s00280-002-0477-8

Cite this article as:
Hotfilder, M., Lanvers, C., Jürgens, H. et al. Cancer Chemother Pharmacol (2002) 50: 167. doi:10.1007/s00280-002-0477-8

Heading

Abstract

Purpose. In order to determine whether Ewing tumour patients may be potential candidates for imatinib mesylate therapy, we analysed the expression of the currently known imatinib mesylate-sensitive tyrosine kinases and tested sensitivity to imatinib mesylate in a panel of eight Ewing tumour cell lines in vitro.

Methods. Expression of the different tyrosine kinases was assessed by flow cytometry and RT-PCR. Sensitivity to imatinib mesylate was analysed using a standard MTT proliferation assay.

Results. Flow cytometric and RT-PCR analyses in a panel of eight Ewing tumour cell lines demonstrated expression of several imatinib mesylate-sensitive tyrosine kinases, including c-KIT, platelet-derived growth factor receptor, c-ABL and c-ARG. However, in the MTT proliferation assay, all eight Ewing tumour cell lines were found to be resistant to imatinib mesylate at concentrations ranging from 0.1 to 10 µM.

Conclusions. Despite the expression of imatinib mesylate-sensitive tyrosine kinases, Ewing tumour cells proved resistant to imatinib mesylate in vitro. This observation has implications for the selection of patients for experimental therapy with imatinib mesylate.

Ewing tumour Sarcoma c-kit Imatinib mesylate (STI571) Signal transduction inhibitor
Download to read the full article text

Copyright information

© Springer-Verlag 2002